Icagen and Pfizer have initiated dosing of a sodium channel-based compound for the treatment of pain and related disorders in a Phase I study in healthy volunteers.
In the first two cohorts of healthy volunteers, the safety, tolerability, pharmacokinetics and optimal formulation of the candidate compound will be evaluated during a placebo-controlled dose escalation.
In the third cohort of healthy volunteers, exploratory pharmacodynamic endpoints will be evaluated.
Icagen CEO P Kay Wagoner said that the company was delighted to initiate Phase I clinical studies of its potent and subtype-selective Nav1.7 compound, in collaboration with Pfizer.
“This marks another important milestone in our development of subtype-selective sodium-channel blockers, which we believe represent a promising approach for the treatment of pain and related disorders,” Wagoner added.